Evidence map›Paper›PMID 39995554›Full record

ArticleWorld journal of clinical oncology2025

Mapping the landscape of gastric signet ring cell carcinoma: Overcoming hurdles and charting new paths for advancement.

Shu-Yuan Wang, Jing-Hang Wang, Run-Kai Chen, Zhen Yuan, Hao Cui, Bo Wei, Jian-Xin Cui

Abstract read
In one paragraph

Article in World journal of clinical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Shu-Yuan WangSchool of Medicine, Nankai University, Tianjin 300071, China.
Jing-Hang WangSchool of Medicine, Nankai University, Tianjin 300071, China.
Run-Kai ChenDepartment of General Surgery, The First Medical Center, Chinese PLA General Hospital, Beijing 100853, China.
Zhen YuanSchool of Medicine, Nankai University, Tianjin 300071, China.
Hao CuiSchool of Medicine, Nankai University, Tianjin 300071, China.
Bo WeiDepartment of General Surgery, The First Medical Center, Chinese PLA General Hospital, Beijing 100853, China. weibo@301hospital.com.cn.
Jian-Xin CuiDepartment of General Surgery, The First Medical Center, Chinese PLA General Hospital, Beijing 100853, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundIn recent years, the global prevalence of gastric cancer (GC) has witnessed a progressive decrease, accompanied by a step-growth in the incidence of gastric signet ring cell carcinoma (GSRCC). As precision medicine concepts progress, GSRCC, a distinct sub-type of GC, has drawn considerable attention from researchers. However, there still persist some controversies regarding the associated research findings.

aimTo summarize the current obstacles and potential future directions for research on GSRCC.

methodsTo begin with, all literature related to GSRCC published from January 1, 2004 to December 31, 2023 was subjected to bibliometric analysis in this article. Additionally, this paper analyzed the research data using CiteSpace, GraphPad Prism v8.0.2, and VOSviewer, which was obtained from the Web of Science Core Collection database. The analysis results were visually represented.

resultsThis study provided a comprehensive overview of the statistical characteristics of the 995 English articles related to GSRCC, including cited references, authors, journals, countries, institutions, and keywords. The popular keywords and clusters contain "prognosis", "survival", "expression", "histology", and "chemotherapy".

conclusionThe prognosis, precise definition and classification, as well as chemoresistance of GSRCC, continue to be crucial areas of ongoing research, whose directions are closely tied to advancements in molecular biology research on GSRCC.

Indexed as

Bibliometric analysisCiteSpaceGastric cancerSignet ring cell carcinomaVOSviewer

Identifiers

PMID39995554
PMCPMC11686557

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.